Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Loss of ELF5–FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling
Snahlata Singh, Sushil Kumar, Ratnesh K. Srivastava, et al.
Nature Cell Biology (2020) Vol. 22, Iss. 5, pp. 591-602
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Roles of IFN-γ in tumor progression and regression: a review
Dragica Jorgovanović, Mengjia Song, Liping Wang, et al.
Biomarker Research (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 859
Neutrophils in cancer: heterogeneous and multifaceted
Catherine C. Hedrick, Ilaria Malanchi
Nature reviews. Immunology (2021) Vol. 22, Iss. 3, pp. 173-187
Closed Access | Times Cited: 485
Clinical significance of FBXW7 loss of function in human cancers
Jingyi Fan, Marcia Bellon, Mingyi Ju, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 88
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
Gaopeng Li, Jae Eun Choi, Ilona Kryczek, et al.
Cancer Cell (2023) Vol. 41, Iss. 2, pp. 304-322.e7
Open Access | Times Cited: 85
Hallmarks of cancer stemness
Jia-Jian Loh, Stephanie Ma
Cell stem cell (2024) Vol. 31, Iss. 5, pp. 617-639
Closed Access | Times Cited: 68
Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer
Asif Ahmad Bhat, Ahsas Goyal, Riya Thapa, et al.
Cytokine (2023) Vol. 171, pp. 156376-156376
Closed Access | Times Cited: 49
Immature natural killer cells promote progression of triple-negative breast cancer
Gatha Thacker, Samantha Henry, Ajeya Nandi, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 686
Closed Access | Times Cited: 44
Type I and II Interferons in the Anti-Tumor Immune Response
Sarah E. Fenton, Diana Saleiro, Leonidas C. Platanias
Cancers (2021) Vol. 13, Iss. 5, pp. 1037-1037
Open Access | Times Cited: 95
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
Michelle von Locquenghien, Catalina Rozalén, Toni Celià-Terrassa
Journal of Clinical Investigation (2021) Vol. 131, Iss. 1
Open Access | Times Cited: 92
Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy
Jiashu Han, Mengwei Wu, Ziwen Liu
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 42
Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
Xingyu Chen, Lixiang Feng, Yujing Huang, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 104-104
Open Access | Times Cited: 39
MLL3 loss drives metastasis by promoting a hybrid epithelial–mesenchymal transition state
Jihong Cui, Chi Zhang, Ji‐Eun Lee, et al.
Nature Cell Biology (2023) Vol. 25, Iss. 1, pp. 145-158
Open Access | Times Cited: 38
IFNγ-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy
Laurent Beziaud, C. Megan Young, Angela Madurga Alonso, et al.
Cell stem cell (2023) Vol. 30, Iss. 6, pp. 818-831.e6
Open Access | Times Cited: 37
KMT2C and KMT2D aberrations in breast cancer
Emily Tinsley, Philip Bredin, Sinéad Toomey, et al.
Trends in cancer (2024) Vol. 10, Iss. 6, pp. 519-530
Closed Access | Times Cited: 11
Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma
Wei‐Ting Kuo, Yi‐Chen Lee, Jia-Bin Liao, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
Georgi Apriamashvili, David W. Vredevoogd, Oscar Krijgsman, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 32
Identification of INFG/STAT1/NOTCH3 as γ-Mangostin's potential targets for overcoming doxorubicin resistance and reducing cancer-associated fibroblasts in triple-negative breast cancer
Bashir Lawal, Alexander T.H. Wu, Chien-Hsin Chen, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114800-114800
Open Access | Times Cited: 17
FBXW7 in breast cancer: mechanism of action and therapeutic potential
Siyu Chen, Ping Leng, Jinlin Guo, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 17
ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
Masanori Oshi, Stephanie Newman, Vijayashree Murthy, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 2758-2758
Open Access | Times Cited: 40
Double-edged effects of interferons on the regulation of cancer-immunity cycle
Xiao Zhang, Song Wang, Yuanyuan Zhu, et al.
OncoImmunology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 34
MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer
Masayuki Hagiwara, Atsushi Fushimi, Atrayee Bhattacharya, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 27
Mechanistic insights into the interplays between neutrophils and other immune cells in cancer development and progression
Zimam Mahmud, Atiqur Rahman, Israt Dilruba Mishu, et al.
Cancer and Metastasis Reviews (2022) Vol. 41, Iss. 2, pp. 405-432
Closed Access | Times Cited: 26
Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling
Qiang Chen, Shuqing Zhuang, Yilin Hong, et al.
Oncogene (2022) Vol. 41, Iss. 10, pp. 1421-1433
Closed Access | Times Cited: 25
HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer
Garyfallia Pantelaiou‐Prokaki, Iga K. Mieczkowska, G. Schmídt, et al.
Clinical Epigenetics (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 25
Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7
Matteo Boretto, Maarten H. Geurts, Shashank Gandhi, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 12
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top